* Repro Med Systems Inc KRMD.OQ KRMD.O is expected to show a
fall in quarterly revenue when it reports results on November
10.
* The Chester New York, New York-based company is expected to
report a 10.9% decrease in revenue to $5.416 million from $6.08
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Repro Med Systems Inc
is for a loss of 2 cents per share. For the same quarter last
year, the company reported earnings of 1 cents per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Repro Med
Systems Inc is $5, about 50.2% above its last closing price
of $2.49.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 -0.02 -0.02 -0.03 Missed -50
Mar. 31 2021 -0.01 -0.01 -0.03 Missed -349.8
Dec. 31 2020 -0.02 -0.01 -0.02 Missed -199.8
Sep. 30 2020 0.02 0.02 0.01 Missed -51.8
Jun. 0.02 0.02 -0.03 Missed -250
30 2020
Mar. 31 2020 0.01 0.01 Met 0
Dec. 31 2019 0.01 0.00 Missed -100
Sep. 30 2019 0.00 0.00 0.02 Beat
This summary was machine generated October 30 at 00:24 GMT. All
figures in US dollars unless otherwise stated